Programmable RNA Therapeutics

Programming Biology.
Restoring Human Function.

Engineering RNA medicines that instruct cells to produce therapeutic proteins and silence disease genes.

Our Pipeline Our Technology Partner With Us

Our Approach

The Next Generation of RNA Therapeutics

Instead of simply delivering proteins or permanently editing genomes, we develop programmable RNA therapeutics that enable transient, controllable biological functions inside human cells.

Our proprietary RNA engineering platform supports multiple therapeutic modalities from a common manufacturing framework, accelerating development while maintaining the flexibility required for different diseases.

Applications

Regenerative Medicine Cell Engineering Epigenetic Therapeutics Gene Regulation Immunotherapy

Lead Clinical Program

Functional Human Collagen I Replacement

AG-101

A First-in-Class Regenerative RNA Therapeutic

AG-101 delivers optimized mRNA encoding functional human Type I collagen, enabling transient de novo production of native collagen I following lipid nanoparticle delivery.

Unlike approaches that stimulate endogenous collagen synthesis, AG-101 directly supplies the genetic instructions required for cells to produce and secrete mature collagen.

Medical Applications

  • Radiation-induced dermal atrophy
  • Dermal reconstruction
  • Soft tissue regeneration
  • Chronic collagen deficiency disorders
  • Future reconstructive indications
Development Stage: Advanced Preclinical
Dermal structure — collagen, fibroblast, and elastin layers
Extracellular matrix components — collagen triple helix, proteoglycan, integrin
Histological cross-section of dermal collagen fibers

Pipeline

Therapeutic Programs

Program
Modality
Stage

AG-101 Functional Human Collagen I

Protein Replacement
Advanced Preclinical

Functional Human Collagen II

Protein Replacement
Discovery

Programmable Cell Engineering

Cell Therapy Platform
Discovery

Epigenetic Therapeutics

Gene Regulation
Discovery

Technology

Programmable RNA Engineering Platform

Our proprietary RNA engineering technologies enable transient cellular programming across multiple therapeutic applications.

Core Capabilities

Large RNA engineering
Polycistronic RNA design
Protein replacement
Gene regulation
Cell engineering
Lipid nanoparticle delivery
Modular therapeutic architecture

Advantages

Why Astral Genetics

One Platform

Supports multiple therapeutic modalities.

Transient Biology

Programmable function without permanent genome modification.

Rapid Development

Shared manufacturing and formulation strategies accelerate translation.

Broad Clinical Potential

Applications spanning regenerative medicine, oncology, immunology, and rare disease.

Market Opportunity

Functional Human Collagen I

Market
Estimated Value
Wound Healing
~$25B
Advanced Wound Care
~$16B
Skin Regeneration
~$20B
Reconstructive Medicine
~$15B
Tissue Engineering
~$12B

Combined Addressable Opportunity

>$70B

Wound healing and skin regeneration process — hemostasis, inflammation, proliferation, remodeling
Normal wound healing vs radiation-induced fibrosis pathway
Collagen scaffold in wound healing — damaged tissue, scaffold, new tissue growth

Roadmap

Development Roadmap

Patent Filing

Complete

Preclinical

In Progress

Pre-IND

IND

Clinical Trials

Current Focus: AG-101 Advanced Preclinical

Completing preclinical validation for Functional Human Collagen I Replacement ahead of Pre-IND preparation.

Collaborate

Partnership Opportunities

We welcome strategic collaborations to advance programmable RNA therapeutics and expand the reach of our platform.

Start a Collaboration Request Deck
Pharmaceutical partnerships
Licensing
Co-development
Government funding
Strategic investment

Company

Driven by science.
Built for impact.

Astral Genetics is advancing a new class of RNA therapeutics designed to address the most challenging diseases — where precision, scale, and coordination are essential. We combine innovative molecular design with next-generation delivery systems to transform genetic medicine from fragmented solutions into unified platforms.